Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
46%
Infliximab
25%
Clostridium Difficile Infection
18%
Caregiver Burden
14%
Antibiotics
14%
Gastroenterology
14%
Health Problems
12%
Anti-tumor Necrosis Factor Therapy
12%
Infusion Interval
12%
Interval Halving
12%
Postoperative Complications
12%
Clostridioides Difficile
12%
Life Strategy
12%
Caregivers
12%
Coping Strategies
12%
Quality of Life
12%
Immunomodulator
12%
Antibiotic Combination
12%
Adult Patients
12%
Anti-TNF Agents
12%
Viral Infection
12%
Gastroenterologist
12%
Loss of Response
12%
Diffusion-weighted Imaging
12%
Apparent Diffusion Coefficient
12%
Web Search
12%
Active Crohn's Disease
12%
Willingness to Accept
12%
Small Bowel Imaging
12%
Ktrans
12%
Dynamic Contrast-enhanced MR Imaging
12%
Terminal Ileum
10%
World Wide Web
10%
Ulcerative Colitis Patient
8%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
7%
Crohn's Colitis
7%
Patient Outcomes
6%
Safety Concerns
6%
Potential Infection
6%
Clinically Significant
6%
Serious Infection
6%
Inflammatory Bowel Disease Treatment
6%
Early Recognition
6%
Immunosuppressive Medication
6%
Perianal Crohn's Disease
6%
Tumor Necrosis Factor Antagonist
6%
Physician Awareness
6%
Adalimumab
6%
Preventive Strategies
6%
Medicine and Dentistry
Inflammatory Bowel Disease
56%
Crohn's Disease
35%
Patient with Inflammatory Bowel Disease
29%
Clostridium Difficile Infection
20%
Gastroenterology
17%
Patient with Crohn's Disease
15%
Antibiotics
14%
Virus Infection
12%
Immunomodulating Agent
12%
Infection
12%
Terminal Ileum
12%
Diffusion MRI
12%
Peptoclostridium difficile
12%
Infusion
12%
Immunosuppressant
12%
Infliximab
12%
Magnetic Resonance Imaging
12%
Antimicrobial Agent
12%
Diseases
12%
Dynamic Contrast-Enhanced MRI
9%
Combination Therapy
7%
Tumor Necrosis Factor
6%
Awareness
6%
Inflammatory Bowel Disease Therapy
6%
Ileum
6%
Biological Product
6%
Drug Dose Intensification
5%
Odds Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
62%
Crohn's Disease
33%
Infliximab
22%
Tumor Necrosis Factor Inhibitor
14%
Diseases
14%
Immunomodulating Agent
12%
Peptoclostridium difficile
12%
Virus Infection
12%
Antibiotics
12%
Immunosuppressive Agent
12%
Postoperative Complication
12%
Tumor Necrosis
12%
Antimicrobial Agent
12%
Ulcerative Colitis
11%
Combination Therapy
11%
Tumor Necrosis Factor
10%
Infection
8%
Biological Product
6%
Clostridium Difficile Infection
6%